Dilated cardiomyopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dilated cardiomyopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability https://clinicaltrials.eu/trial/a-study-of-danicamtiv-for-adults-with-symptomatic-genetic-and-familial-dilated-cardiomyopathy-to-test-if-it-improves-heart-function-and-exercise-ability/ Wed, 29 Apr 2026 15:08:16 +0000 https://clinicaltrials.eu/trial/a-study-of-danicamtiv-for-adults-with-symptomatic-genetic-and-familial-dilated-cardiomyopathy-to-test-if-it-improves-heart-function-and-exercise-ability/ This study is looking at a condition called dilated cardiomyopathy, which is a disease where the heart muscle becomes weakened and stretched, making it harder for the heart to pump blood effectively. This particular study focuses on people who have this condition because of changes in their genes that they were born with or that run in their family. The treatment being tested is called danicamtiv, which is also known by the code names BMS-986434 and MYK-491. Some people in the study will receive danicamtiv tablets while others will receive placebo tablets.

The purpose of this study is to find out if danicamtiv can help improve heart function and exercise ability in people with this genetic form of heart muscle disease. The study is divided into two parts. In the first part, the researchers will use a heart imaging test called transthoracic echocardiogram, which is an ultrasound of the heart, to see if the medication affects how well the heart works. In the second part, they will use cardiopulmonary exercise testing, which measures how much oxygen the body uses during exercise, to see if the medication helps people exercise better. The study will measure these changes over a period of 26 weeks.

During the study, participants will take either danicamtiv or placebo tablets by mouth for up to 26 weeks. The study uses a method where neither the participants nor the doctors know who is receiving the actual medication and who is receiving the placebo. Participants will need to attend regular visits where they will have heart ultrasounds and exercise tests to check how their heart is functioning and how well they can exercise. The study is looking at people who are at least 18 years old and have symptoms of this genetic heart condition with an enlarged left side of the heart.

]]> Study on Early Use of Ivabradine for Children with Heart Failure Due to Dilated Cardiomyopathy https://clinicaltrials.eu/trial/study-on-early-use-of-ivabradine-for-children-with-heart-failure-due-to-dilated-cardiomyopathy/ Wed, 29 Apr 2026 15:04:01 +0000 https://clinicaltrials.eu/trial/study-on-early-use-of-ivabradine-for-children-with-heart-failure-due-to-dilated-cardiomyopathy/ This clinical trial is focused on studying the effects of a medication called Ivabradine in children who have a heart condition known as acute heart failure due to dilated cardiomyopathy. Dilated cardiomyopathy is a disease where the heart becomes enlarged and cannot pump blood effectively. The purpose of the study is to evaluate how well Ivabradine can help manage heart rate in these young patients.

Participants in the study will receive Ivabradine in the form of film-coated tablets. The study will observe the effects of the medication over a period of time, starting with 14 days of stable therapy. During this time, researchers will monitor changes in heart rate and other health indicators. The study will also include a follow-up period of four months to assess longer-term effects.

The trial aims to understand how Ivabradine affects heart rate and other related health measures, such as the levels of a heart-related protein called NT-proBNP and the function of the heart’s left ventricle, which is the chamber responsible for pumping oxygen-rich blood to the body. The results will help determine the potential benefits of early administration of Ivabradine in children with this heart condition.

]]> Study of Risedronate Sodium for Patients with Dilated Cardiomyopathy Due to Troponin T Gene Mutation https://clinicaltrials.eu/trial/study-of-risedronate-sodium-for-patients-with-dilated-cardiomyopathy-due-to-troponin-t-gene-mutation/ Wed, 29 Apr 2026 15:00:13 +0000 https://clinicaltrials.eu/trial/study-of-risedronate-sodium-for-patients-with-dilated-cardiomyopathy-due-to-troponin-t-gene-mutation/ This clinical trial is focused on studying a heart condition known as dilated cardiomyopathy. This condition affects the heart’s ability to pump blood efficiently because the heart’s main pumping chamber, the left ventricle, becomes enlarged and weakened. In this study, researchers are investigating a specific cause of this condition, which is a change in the Troponin T gene due to a K210 deletion. The treatment being tested is a medication called Risedronate, which is usually taken as a 10 mg film-coated tablet. The purpose of the study is to see if taking Risedronate can improve heart function in patients with this specific genetic alteration.

Participants in the study will take Risedronate daily for a period of up to 12 months. Throughout the study, the heart’s function will be monitored using an echocardiogram, which is a type of ultrasound that creates images of the heart. The main focus is to observe any changes in the heart’s pumping ability over a six-month period. Additionally, the study will look at whether there is an improvement in the participants’ ability to perform physical activities, which will be assessed through a stress test that measures oxygen consumption.

This trial aims to provide valuable insights into whether Risedronate can be an effective treatment for improving heart function in patients with dilated cardiomyopathy caused by the K210 deletion in the Troponin T gene. The study is expected to continue until mid-2026, with recruitment of participants starting in mid-2024.

]]> Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-ab-1002-for-adults-with-class-iii-heart-failure-and-non-ischemic-cardiomyopathy/ Wed, 29 Apr 2026 14:59:41 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-ab-1002-for-adults-with-class-iii-heart-failure-and-non-ischemic-cardiomyopathy/ This study focuses on patients with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure, a condition where the heart muscle becomes weak and enlarged, making it difficult to pump blood effectively throughout the body. The research evaluates a new gene therapy called AB-1002, which is given as a single injection directly into the heart’s arteries.

The purpose of this research is to determine how well AB-1002 works and how safe it is compared to placebo in treating heart failure. The treatment involves a one-time delivery of the medication through intracoronary infusion, which means the medicine is administered directly into the blood vessels that supply the heart muscle.

During the study, participants will be monitored for one year after receiving either AB-1002 or placebo. The research will track changes in heart function, exercise capacity, and overall well-being. AB-1002 is a type of gene therapy that uses a modified virus to deliver genetic material designed to help improve heart function in people with heart failure.

]]> Study on the Effectiveness of Autologous Bone Marrow Cells for Patients with Dilated Cardiomyopathy and Heart Failure https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-autologous-bone-marrow-cells-for-patients-with-dilated-cardiomyopathy-and-heart-failure/ Wed, 29 Apr 2026 14:58:31 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-autologous-bone-marrow-cells-for-patients-with-dilated-cardiomyopathy-and-heart-failure/ This clinical trial is focused on studying a heart condition known as idiopathic dilated cardiomyopathy, which is a type of heart failure where the heart becomes enlarged and cannot pump blood efficiently. The trial is testing a new treatment involving the use of autologous bone marrow-derived adult mononuclear cells. These are special cells taken from a patient’s own bone marrow and are not expanded or grown in a lab before being injected back into the patient. The treatment is given through a method called intracoronary infusion, which means the cells are delivered directly into the heart’s blood vessels.

The purpose of the study is to see if this treatment can help improve heart function in patients with this condition, for which there are currently no effective treatments. Participants in the study will receive either the cell treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will undergo various assessments to monitor changes in their heart function and overall health. These assessments include clinical evaluations, heart imaging tests, and exercise tests. The study aims to determine if the treatment can lead to better heart function and fewer heart-related problems over time. Participants will be closely monitored with regular check-ups and follow-ups to ensure their safety and to gather comprehensive data on the treatment’s effectiveness.

]]> Study on Danicamtiv for Patients with Primary Dilated Cardiomyopathy Due to MYH7 or TTN Gene Variants https://clinicaltrials.eu/trial/study-on-danicamtiv-for-patients-with-primary-dilated-cardiomyopathy-due-to-myh7-or-ttn-gene-variants/ Wed, 29 Apr 2026 14:23:30 +0000 https://clinicaltrials.eu/trial/study-on-danicamtiv-for-patients-with-primary-dilated-cardiomyopathy-due-to-myh7-or-ttn-gene-variants/ This clinical trial is focused on studying a heart condition known as Primary Dilated Cardiomyopathy, which is a type of heart failure where the heart becomes enlarged and cannot pump blood efficiently. This condition can be caused by genetic mutations, specifically in the MYH7 or TTN genes, or other causes. The study is testing a new treatment called Danicamtiv, which is taken as a tablet by mouth. Danicamtiv is being developed to help improve heart function in people with this condition.

The purpose of the study is to explore the safety and initial effectiveness of Danicamtiv in patients who are stable and able to walk around. Participants will receive Danicamtiv and will be monitored for any side effects and changes in their heart function. The study will last for a period of time, during which participants will take the medication and have regular check-ups to assess their heart health.

Throughout the study, participants will have their heart function evaluated using tests like echocardiograms, which are ultrasound tests that look at how well the heart is working. The study aims to gather information on how well Danicamtiv is tolerated and its potential benefits for improving heart function in people with Primary Dilated Cardiomyopathy due to genetic mutations or other causes.

]]> Study on Early Use of Candesartan vs Placebo for People with Genetic Risk of Dilated Cardiomyopathy https://clinicaltrials.eu/trial/study-on-early-use-of-candesartan-vs-placebo-for-people-with-genetic-risk-of-dilated-cardiomyopathy/ Wed, 29 Apr 2026 14:23:25 +0000 https://clinicaltrials.eu/trial/study-on-early-use-of-candesartan-vs-placebo-for-people-with-genetic-risk-of-dilated-cardiomyopathy/ This clinical trial is focused on studying a heart condition known as dilated cardiomyopathy (DCM). DCM is a disease where the heart becomes enlarged and cannot pump blood efficiently. The study is specifically looking at individuals who carry genetic variants that can cause DCM but do not yet show symptoms of the disease. The treatment being tested is a medication called candesartan, which is commonly used to treat high blood pressure and heart failure. In this trial, candesartan is being compared to a placebo to see if it can prevent changes in the heart that are associated with DCM.

The purpose of the study is to determine if early treatment with candesartan can prevent a significant decline in the heart’s ability to pump blood, known as left ventricular ejection fraction (LVEF), or an increase in the size of the heart’s main pumping chamber, known as left ventricular end-diastolic volume (LVEDV). Participants in the study will be randomly assigned to receive either candesartan or a placebo. The study will monitor changes in LVEF and LVEDV over time using magnetic resonance imaging (MRI), a type of scan that provides detailed images of the heart.

The trial will last for several years, during which participants will have regular check-ups and MRI scans to track any changes in their heart function. The study aims to see if candesartan can help prevent the progression of DCM in people who are at risk but do not yet have symptoms. This research could provide valuable insights into the early treatment of DCM and potentially improve outcomes for those with a genetic predisposition to the disease.

]]> Study on Anakinra for Treating Inflammatory Dilated Cardiomyopathy in Patients: Evaluating Efficacy and Safety of Anakinra with Standard Care vs. Standard Care Alone https://clinicaltrials.eu/trial/study-on-anakinra-for-treating-inflammatory-dilated-cardiomyopathy-in-patients-evaluating-efficacy-and-safety-of-anakinra-with-standard-care-vs-standard-care-alone/ Wed, 29 Apr 2026 14:23:02 +0000 https://clinicaltrials.eu/trial/study-on-anakinra-for-treating-inflammatory-dilated-cardiomyopathy-in-patients-evaluating-efficacy-and-safety-of-anakinra-with-standard-care-vs-standard-care-alone/ This clinical trial is focused on studying a heart condition known as inflammatory dilated cardiomyopathy. This condition affects the heart’s ability to pump blood effectively due to inflammation, leading to symptoms like fatigue and shortness of breath. The trial will test a treatment called anakinra, which is a medication designed to reduce inflammation by blocking a specific protein in the body. The study will compare the effects of anakinra combined with standard heart care to standard heart care alone.

The purpose of the study is to evaluate whether anakinra can improve heart function in patients with inflammatory dilated cardiomyopathy. Participants will receive either anakinra or a placebo, in addition to their usual heart treatment. The study will last for a period of 12 weeks, during which participants will be monitored to assess any changes in their heart’s ability to pump blood, measured by a test called transthoracic echocardiography (TTE). This test uses sound waves to create images of the heart and evaluate its function.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to determine if anakinra can help improve the heart’s pumping ability, which is measured by the left ventricular ejection fraction (LVEF). This trial aims to provide valuable information on the potential benefits of anakinra for patients with this specific type of heart disease.

]]>